Raj Vuppalanchi, Karan Mathur, Maximillian Pyko, Niharika Samala, Naga Chalasani – 17 July 2018 – Noncirrhotic portal hypertension (NCPH) is often a diagnostic challenge due to signs and symptoms of portal hypertension that overlap with cirrhosis. The etiology of NCPH is broadly classified as prehepatic, hepatic (presinusoidal and sinusoidal) and posthepatic. Some common etiologies of NCPH encountered in clinical practice include portal vein thrombosis (prehepatic) and nodular regenerative hyperplasia (hepatic).

Raj Vuppalanchi, Karan Mathur, Maximillian Pyko, Niharika Samala, Naga Chalasani – 17 July 2018 – Noncirrhotic portal hypertension (NCPH) is often a diagnostic challenge due to signs and symptoms of portal hypertension that overlap with cirrhosis. The etiology of NCPH is broadly classified as prehepatic, hepatic (presinusoidal and sinusoidal) and posthepatic. Some common etiologies of NCPH encountered in clinical practice include portal vein thrombosis (prehepatic) and nodular regenerative hyperplasia (hepatic).

Eva Román, Cristina Gely, Montse Flavià, Maria Poca, Edilmar Alvarado, Víctor Vargas, Carlos Guarner, Germán Soriano – 17 July 2018

Yoosoo Chang, Yong Kyun Cho, Yejin Kim, Eunju Sung, Jiin Ahn, Hyun‐Suk Jung, Kyung Eun Yun, Hocheol Shin, Seungho Ryu – 17 July 2018 – The effect of modest alcohol consumption on fibrosis progression in the general population with nonalcoholic fatty liver disease (NAFLD) remains unclear. We examined the association of nonheavy alcohol consumption with worsening of noninvasive fibrosis indices in a large‐scale, low‐risk population with NAFLD. A cohort study was performed in 58,927 Korean adults with NAFLD and low fibrosis scores who were followed for a median of 4.9 years.

Chia‐Ming Chu, Yun‐Fan Liaw – 16 July 2018

Sih‐Han Liao, Tung‐Hung Su, Yung‐Ming Jeng, Po‐Chin Liang, Ding‐Shinn Chen, Chien‐Hung Chen, Jia‐Horng Kao – 16 July 2018 – Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer‐related deaths worldwide. Sarcomatoid HCC is a rare histological subtype of HCC with largely unclear clinical manifestations and outcomes. We evaluated the clinical manifestations and outcomes of patients with sarcomatoid HCC.

Donghee Kim, Andrew A. Li, Brandon J. Perumpail, Chiranjeevi Gadiparthi, Won Kim, George Cholankeril, Jeffrey S. Glenn, Stephen A. Harrison, Zobair M. Younossi, Aijaz Ahmed – 16 July 2018 – With recent improvements in the treatment of end‐stage liver disease (ESLD), a better understanding of the burden of cirrhosis and hepatocellular carcinoma (HCC) is needed in the United States. A population‐based study using the US Census and national mortality database was performed.

Changhui Zhou, Weihua Wang, Ying Mu – 16 July 2018

Marina Bárcena‐Varela, Stefano Caruso, Susana Llerena, Gloria Álvarez‐Sola, Iker Uriarte, M. Ujue Latasa, Raquel Urtasun, Sandra Rebouissou, Laura Alvarez, Maddalen Jimenez, Eva Santamaría, Carlos Rodriguez‐Ortigosa, Giuseppe Mazza, Krista Rombouts, Edurne San José‐Eneriz, Obdulia Rabal, Xabier Agirre, Maria Iraburu, Alvaro Santos‐Laso, Jesus M. Banales, Jessica Zucman‐Rossi, Felipe Prósper, Julen Oyarzabal, Carmen Berasain, Matías A. Ávila, Maite G.

Samuel J. Daniels, Diana J. Leeming, Mohammed Eslam, Ahmed M. Hashem, Mette J. Nielsen, Aleksander Krag, Morten A. Karsdal, Jane I. Grove, Indra Neil Guha, Takumi Kawaguchi, Takuji Torimura, Duncan McLeod, Jun Akiba, Philip Kaye, Bastiaan de Boer, Guruprasad P. Aithal, Leon A. Adams, Jacob George – 16 July 2018 – Given the high global prevalence of nonalcoholic fatty liver disease (NAFLD), the need for relevant noninvasive biomarkers and algorithms to accurately stage disease severity is a critical unmet medical need.